Northern Trust Corp Has $260.48 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Northern Trust Corp has reduced its stake in Zimmer Biomet Holdings, Inc. to 2.9%, selling 68,780 shares and now owning approximately 1.16% of the company, valued at $260 million.
• Zimmer Biomet's recent quarterly earnings reported $2.07 EPS, exceeding analysts' expectations of $1.98, with revenue increasing by 7.0% year-over-year to $2.08 billion.
• The company declared a quarterly dividend of $0.24, with a resulting annual dividend yield of 0.9%, reflecting a payout ratio of 23.36%.

Northern Trust Corp lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 2.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,301,444 shares of the medical equipment provider's stock after selling 68,780 shares during the quarter. Northern Trust Corp owned 1.16% of Zimmer Biomet worth $260,477,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in ZBH. Brighton Jones LLC acquired a new stake in shares of Zimmer Biomet during the fourth quarter valued at $204,000. Jump Financial LLC boosted its stake in shares of Zimmer Biomet by 63.8% during the fourth quarter. Jump Financial LLC now owns 3,268 shares of the medical equipment provider's stock valued at $345,000 after acquiring an additional 1,273 shares during the last quarter. NewEdge Advisors LLC boosted its stake in shares of Zimmer Biomet by 72.6% during the fourth quarter. NewEdge Advisors LLC now owns 4,713 shares of the medical equipment provider's stock valued at $498,000 after acquiring an additional 1,983 shares during the last quarter. First Trust Advisors LP raised its holdings in Zimmer Biomet by 8.2% in the 4th quarter. First Trust Advisors LP now owns 324,473 shares of the medical equipment provider's stock valued at $34,274,000 after acquiring an additional 24,671 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Zimmer Biomet by 6.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,000,838 shares of the medical equipment provider's stock valued at $211,348,000 after acquiring an additional 126,151 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

ZBH stock traded up $3.2070 during trading on Friday, reaching $107.6270. 1,099,322 shares of the company's stock were exchanged, compared to its average volume of 1,763,578. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $116.71. The company's fifty day moving average price is $95.52 and its 200-day moving average price is $99.26. The firm has a market cap of $21.32 billion, a PE ratio of 26.19, a P/E/G ratio of 2.12 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter in the previous year, the business earned $2.01 EPS. The company's quarterly revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, June 26th. Zimmer Biomet's dividend payout ratio is presently 23.36%.

Insiders Place Their Bets

In other news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the sale, the insider owned 20,424 shares in the company, valued at approximately $1,940,280. This represents a 4.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.39% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Robert W. Baird dropped their target price on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. JMP Securities dropped their target price on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Evercore ISI dropped their target price on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a report on Tuesday, July 8th. UBS Group raised their target price on Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a report on Friday, August 8th. Finally, Wells Fargo & Company dropped their target price on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Nine research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of "Hold" and a consensus target price of $111.44.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.